Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative adjuvant TACE plus targeted therapy and PD-1 inhibitor for hepatocellular carcinoma
ChiCTR2300072663Phase 2Not yet recruiting
- Sponsor
- The Second Department of Hepatobiliary Surgery of Guizhou Provincial People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Transcatheter Arterial Chemoembolization in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Second Department of Hepatobiliary Surgery of Guizhou Provincial People's Hospital. Primary endpoint: 3-year overall survival rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Transcatheter Arterial Chemoembolization
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300072663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072663.